Intralesional interferon alfa-2b treatment of condylomata acuminata previously resistant to podophyllum resin application

J M BOOT, F B BLOG, E STOLZ

From the Department of Dermatovenerology, University Hospital Rotterdam-Dijkzigt, Rotterdam, The Netherlands

SUMMARY The safety and efficacy of intralesionally administered interferon alfa-2b were assessed in 11 patients suffering from condylomata acuminata for four to 10 months for whom application of podophyllum resin had proved unsuccessful. Three warts from each patient were injected with 10⁶ IU interferon alfa-2b three times a week for three weeks. Treatment was followed by a 13 week observation period.

Interferon alfa-2b treatment resulted in a highly significant (p < 0.0001) reduction in the mean size of the treated warts, which decreased from an initial size of 29 mm² to 2–3 mm² by week 16. In six out of the 10 patients completing the trial, both the test condylomata and adjacent control warts cleared completely; a recurrence was observed in one of these six patients. Influenza like symptoms (headache and myalgia) were the most common side effects reported, though they were mild in nature and not disabling. These results corroborate those of previous trials with interferon preparations and indicate that its antiviral activity makes it a possible treatment for this sexually transmitted disorder.

We therefore sought to assess the safety and efficacy of intralesionally injected interferon alfa-2b in patients suffering from genital warts, singling out those in whom podophyllum resin treatment had hitherto proved unsuccessful.

Patients and methods

ENTRY CHARACTERISTICS

Men and women patients aged 18 to 65 and diagnosed as having condylomata acuminata that had proved resistant to podophyllum resin treatment were eligible for inclusion in the trial. The patients were required to be in good general health and to have no history of heart disease, thrombophlebitis, pulmonary embolism, or known sensitivity to any component of the test medication. Women participants were required to be non-pregnant and using a reliable contraceptive method. Patients who had received local or systemic antiviral or antiwart treatment two weeks before the onset of the study or who had undergone cytotoxic or immunosuppressive treatment four weeks before the start of the trial were ineligible to participate. Previous treatment with interferon or interferon inducers also constituted grounds for exclusion. Patients were asked not to take, during the trial, any medication that could...
Interferon alfa-2b to treat condylomata acuminata resistant to podophyllin

Fully completed the trial. The one patient who withdrew had difficulty in complying with the frequency of treatment visits; he did not experience any side effects while receiving treatment.

The treated patients (seven men and three women) were aged 19 to 55 (mean 35) years. Before the trial, podophyllin resin treatment had been unsuccessfully applied for periods ranging from four to 10 months.

Figure 1 shows the changes in wart area for each patient as well as the mean change during the trial. Intraleisional injection of interferon alfa-2b resulted in a highly significant reduction (F value = 32.72; p < 0.0001) in the mean area of the treated condylomata, which decreased from 29 mm$^2$ to 12 mm$^2$ by day 21, and to 2–3 mm$^2$ by week 16. The reduction in wart area was especially noteworthy between days 19 and 21 (p < 0.0001), 21 and 24 (p = 0.0069), and 24 and 26 (p < 0.0001).

In six out of the 10 patients, both the test and control condylomata cleared completely (Fig 2). The test warts disappeared by day 24 (one patient), day 26 (three patients), between weeks four and seven (one patient), and between weeks seven and 12 (one patient). By contrast, the condylomata remained refractory in four patients (two men and two women). A relapse was observed in one woman: all her condylomata had cleared by day 26, but one lesion reappeared during the eighth week at a site that had been injected. In two patients (one man and one woman) condylomata that had shrunk in size began

---

**Intraleisional interferon alfa-2b to treat condylomata acuminata resistant to podophyllin**

Interferon alfa-2b interferes with interferon alfa-2b or modify the natural course of the disease. Informed consent was obtained from all patients before entry.

**STUDY DESIGN AND DATA EVALUATION**

Three warts on each patient were injected intraleionally with $10^6$ IU interferon alfa-2b (Intron A, Essex/Schering) three times a week for three weeks. Clinical efficacy was assessed by measuring the areas of the treated condylomata and comparing the evolution of their mean area with that of two control warts (if present). The wart area was defined as the product of the two largest horizontal dimensions. Measurements were taken at each treatment visit as well as at weeks 4, 6, 12, and 16 after the start of the trial.

Laboratory investigations, including blood chemistry and haematological examinations as well as routine urine analysis, were performed on days 1 and 5 and one week after the end of treatment.

A logarithmic transformation ($\log$(area + 0.5)) was applied to provide a better normally distributed variable. Analysis of variance with repeat measurements was employed for the first seven weeks to assess the significance of changes in the area of the treated warts. P values apply to this seven week period, after which relapse occurred in three patients.

**Results**

Ten out of the 11 patients entering the study successfully completed the trial. The one patient who withdrew had difficulty in complying with the frequency of treatment visits; he did not experience any side effects while receiving treatment.

The treated patients (seven men and three women) were aged 19 to 55 (mean 35) years. Before the trial, podophyllin resin treatment had been unsuccessfully applied for periods ranging from four to 10 months.

Figure 1 shows the changes in wart area for each patient as well as the mean change during the trial. Intraleisional injection of interferon alfa-2b resulted in a highly significant reduction (F value = 32.72; p < 0.0001) in the mean area of the treated condylomata, which decreased from 29 mm$^2$ to 12 mm$^2$ by day 21, and to 2–3 mm$^2$ by week 16. The reduction in wart area was especially noteworthy between days 19 and 21 (p < 0.0001), 21 and 24 (p = 0.0069), and 24 and 26 (p < 0.0001).

In six out of the 10 patients, both the test and control condylomata cleared completely (Fig 2). The test warts disappeared by day 24 (one patient), day 26 (three patients), between weeks four and seven (one patient), and between weeks seven and 12 (one patient). By contrast, the condylomata remained refractory in four patients (two men and two women). A relapse was observed in one woman: all her condylomata had cleared by day 26, but one lesion reappeared during the eighth week at a site that had been injected. In two patients (one man and one woman) condylomata that had shrunk in size began
Fig 2 Disappearance of penile condylomata acuminata after intralesional treatment of two patients with $10^6$ IU interferon alfa-2b three times a week for three weeks. (Left, before treatment; right, after treatment).
Intralesional interferon alfa-2b to treat condylomata acuminata resistant to podophyllin

Table  Side effects that emerged during treatment of genital warts with 10^6 IU interferon alfa-2b three times a week for three weeks

<table>
<thead>
<tr>
<th>Side effects</th>
<th>No of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Influenza like symptoms</td>
<td>6</td>
</tr>
<tr>
<td>Headache</td>
<td>4</td>
</tr>
<tr>
<td>Muscle ache</td>
<td>4</td>
</tr>
<tr>
<td>Irritation at injection site</td>
<td>2</td>
</tr>
<tr>
<td>Malaise</td>
<td>2</td>
</tr>
<tr>
<td>Nausea</td>
<td>1</td>
</tr>
<tr>
<td>Pain in kidney region</td>
<td>1</td>
</tr>
<tr>
<td>Myalgia</td>
<td>1</td>
</tr>
</tbody>
</table>

increasing again (in week 7 and week 12).

Side effects are listed in the table. Six patients reported influenza like symptoms, four experienced muscle ache, and four headache. Two were free of symptoms and three reported mild, persistent side effects throughout most of the three week treatment period. In no case, however, were symptoms severe enough to cause withdrawal from the study. Laboratory variables remained essentially unaltered.

Discussion

In this study of 11 patients, the intralesional administration of interferon alfa-2b for three weeks proved to be effective in eliminating or reducing most of the genital warts treated, which confirms results from previous preliminary or double blind placebo controlled studies. A total cure, however, only occurred in five patients in whom the positive effects of treatment were maintained for 13 weeks after intralesional injection of the interferon preparation. One out of the six patients whose lesions had disappeared suffered a relapse during the study period.

Though adjacent warts were not measured, interferon treatment also seemed to reduce non-treated lesions next to the treated warts during and after interferon treatment. Further testing as to whether HPV might also be affected in the tissues adjacent to the lesions is warranted.

No serious or severe side effects attributable to interferon alfa-2b were reported by any of the patients. The reactions were generally characterised by mild influenza like symptoms, headache, or muscle pain, and did not interfere substantially with the patients' daily activities. None of the patients considered subcutaneous interferon injections with a fine needle (16 × 0.5 mm) to be inordinately painful.

Several different treatment regimens for intralesional and intramuscular administration of interferon alfa-2b have been used to treat condylomata acuminata, which have resulted in differing degrees of success. The results achieved have also depended on the duration of treatment and the length of the follow up period. Although the injection of interferon alfa-2b can be effective in treating genital warts, additional studies must be performed to optimise doses and treatment schedules. In the meantime, intralesional injection of interferon alfa-2b may be considered to be one of the possible treatments for this sexually transmitted disease.

This study was supported by a grant from Essex Nederland. We thank Mr and Mrs F Shapiro (Syntaxis-Belgium) for editorial and technical help with the manuscript.

References